CA
NZ
UK
AU
IND
US
…
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Celldex Therapeutics is a clinical-stage biopharmaceutical company developing targeted immunotherapies and antibody-based treatments for cancer and immune disorders. Long-term growth may be driven by clinical trial progress, regulatory approvals and strategic partnerships that enable commercialization. Investors may find the company attractive for exposure to catalyst-driven oncology and immunology programs that could deliver high upside if trials succeed.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -258.80M | -157.86M | -141.43M | -112.33M | -70.74M |
| Net income | -258.80M | -157.86M | -141.43M | -122.78M | -70.51M |
| Selling general administrative | 43.80M | 38.55M | 30.91M | 27.20M | 20.49M |
| Gross profit | 1.50M | -156.53M | -111.13M | 2.36M | 4.65M |
| Reconciled depreciation | 3.38M | 3.18M | 2.92M | 2.90M | 3.07M |
| Ebit | -258.80M | -195.08M | -142.04M | -115.23M | -71.24M |
| Ebitda | -255.42M | -191.90M | -139.03M | -101.87M | -67.56M |
| Depreciation and amortization | 3.38M | 3.18M | 3.01M | 13.37M | 3.69M |
| Non operating income net other | - | - | - | - | 0.51M |
| Operating income | -287.40M | -195.08M | -154.54M | -115.23M | -71.24M |
| Other operating expenses | 288.90M | 202.10M | 161.43M | 109.45M | 73.80M |
| Interest expense | - | - | - | -2.91M | 0.11M |
| Tax provision | - | - | 0.00M | 0.00M | -0.23M |
| Non recurring | - | - | - | - | 3.50M |
| Income tax expense | - | -157.86M | 2.84M | 10.46M | -0.23M |
| Total revenue | 1.50M | 7.02M | 6.88M | 2.36M | 4.65M |
| Total operating expenses | 288.90M | 38.55M | 43.41M | 109.45M | 73.80M |
| Cost of revenue | - | 163.55M | 118.01M | - | - |
| Total other income expense net | 28.60M | 37.22M | 13.11M | 2.91M | 0.51M |
| Net income from continuing ops | -258.76M | -157.86M | -124.61M | -112.33M | -70.51M |
| Net income applicable to common shares | - | - | - | -112.33M | -70.51M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 582.98M | 792.34M | 465.63M | 352.74M | 444.65M |
| Intangible assets | 27.19M | 27.19M | 27.19M | 31.30M | 30.26M |
| Other current assets | 14.08M | 21.18M | 5.47M | 12.74M | 2.59M |
| Total liab | 55.82M | 45.34M | 36.46M | 26.53M | 25.18M |
| Total stockholder equity | 527.16M | 747.00M | 429.17M | 326.20M | 419.48M |
| Other current liab | 48.26M | 34.78M | 26.02M | 13.82M | 1.55M |
| Common stock | 0.07M | 0.07M | 0.06M | 0.05M | 0.05M |
| Capital stock | 0.07M | 0.07M | 0.06M | 0.05M | 0.05M |
| Retained earnings | -1813.98M | -1555.22M | -1397.36M | -1255.93M | -1143.61M |
| Other liab | - | - | - | 5.33M | 7.35M |
| Other assets | - | - | - | 0.10M | 0.10M |
| Cash | 28.87M | 28.36M | 34.81M | 29.43M | 39.14M |
| Total current liabilities | 50.99M | 39.50M | 31.12M | 18.61M | 16.53M |
| Current deferred revenue | - | - | - | - | 12.00M |
| Net debt | -26.54M | -24.54M | -32.27M | -25.40M | -36.10M |
| Short term debt | 1.55M | 1.45M | 1.61M | 1.45M | 1.75M |
| Short long term debt total | 2.34M | 3.81M | 2.54M | 4.03M | 3.04M |
| Other stockholder equity | 2337.45M | 2298.85M | 1823.17M | 1580.83M | 1561.14M |
| Property plant equipment | - | - | - | 7.75M | 6.52M |
| Total current assets | 534.66M | 747.16M | 431.69M | 317.69M | 410.84M |
| Net tangible assets | - | - | - | 299.01M | 392.29M |
| Short term investments | 489.70M | 696.92M | 386.88M | 275.52M | 369.11M |
| Net receivables | 2.02M | 0.70M | 4.53M | 0.35M | 0.17M |
| Inventory | - | - | 0.00M | -0.35M | -0.17M |
| Accounts payable | 1.18M | 3.27M | 3.49M | 3.34M | 1.23M |
| Accumulated other comprehensive income | 3.63M | 3.31M | 3.31M | 1.26M | 1.89M |
| Common stock total equity | - | - | - | - | 0.05M |
| Retained earnings total equity | - | - | - | - | -1143.61M |
| Non currrent assets other | 13.36M | 9.75M | 0.11M | 0.10M | 0.10M |
| Non current assets total | 48.32M | 45.18M | 33.93M | 35.04M | 33.81M |
| Capital lease obligations | 2.34M | 3.81M | 2.54M | 4.03M | 3.04M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 211.79M | -290.13M | -105.78M | 89.94M | -214.93M |
| Change to liabilities | - | - | - | 3.12M | 3.65M |
| Total cashflows from investing activities | 209.07M | -290.13M | - | 89.94M | -216.16M |
| Total cash from financing activities | 2.39M | 441.45M | 218.46M | 4.08M | 272.37M |
| Change to operating activities | - | - | - | -6.85M | -6.28M |
| Net income | -258.76M | -157.86M | -141.43M | -112.33M | -70.51M |
| Change in cash | 0.52M | -6.46M | 5.38M | -9.71M | -4.69M |
| Begin period cash flow | 28.36M | 34.81M | 29.43M | 39.14M | 43.84M |
| End period cash flow | 28.87M | 28.36M | 34.81M | 29.43M | 39.14M |
| Total cash from operating activities | -210.94M | -157.78M | -107.29M | -103.73M | -60.91M |
| Issuance of capital stock | 0.00M | 432.30M | 216.22M | 0.00M | 269.89M |
| Depreciation | -2.48M | 3.18M | 3.01M | 2.90M | 3.07M |
| Other cashflows from investing activities | -2.71M | -1.92M | - | - | 0.03M |
| Change to account receivables | -1.31M | 1.93M | -2.28M | -0.17M | 1.57M |
| Sale purchase of stock | - | - | - | - | 272.37M |
| Other cashflows from financing activities | 2.39M | 9.15M | 2.24M | 4.08M | 2.48M |
| Change to netincome | - | - | - | 9.60M | 7.59M |
| Capital expenditures | 2.71M | 1.92M | 1.82M | 1.83M | 1.25M |
| Change receivables | - | - | - | - | 1.57M |
| Cash flows other operating | - | - | - | - | -72.39M |
| Cash and cash equivalents changes | - | - | - | - | -4.69M |
| Change in working capital | 14.06M | -21.60M | 13.46M | -3.90M | -1.05M |
| Stock based compensation | 36.22M | 34.24M | 23.89M | 15.61M | 8.95M |
| Other non cash items | 0.01M | -15.73M | -6.22M | -5.79M | -1.14M |
| Free cash flow | -213.66M | -159.70M | -109.11M | -105.56M | -62.16M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CLDX Celldex Therapeutics Inc |
0.21 0.70% |
30.10 | - | - | 19140.33 | 4.31 | 14972.62 | -17.34 |
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
| Name | Title | Year Born |
|---|---|---|
| Mr. Anthony S. Marucci M.B.A. | Founder, Pres, CEO & Director | 1962 |
| Dr. Tibor Keler | Founder, Chief Scientific Officer & Exec. VP | 1959 |
| Mr. Sam Martin | Sr. VP, CFO, Sec. & Treasurer | 1971 |
| Mr. Freddy A. Jimenez Esq. | Sr. VP & Gen. Counsel | 1969 |
| Dr. Diane C. Young M.D. | Sr. VP & Chief Medical Officer | 1957 |
| Prof. Joseph P. Schlessinger Ph.D. | Co-Founder & Member of Scientific Advisory Board | 1945 |
| Ms. Sarah Cavanaugh | Sr. VP of Corp. Affairs & Admin. | 1975 |
| Patrick Till | Sr. Director of Investor Relations & Corp. Communications | NA |
| Dr. Ronald A. Pepin | Chief Bus. Officer & Sr. VP | 1956 |
| Ms. Elizabeth Crowley | Chief Product Devel. Officer & Sr. VP | 1972 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...